Role of angiotensin-converting enzyme 2 (ACE2) in diabetic cardiovascular complications

Clinical Science

Volumn 126, Issue 7, 2014, Pages 471-482

  Patel, Vaibhav B ^a   Parajuli, Nirmal ^a   Oudit, Gavin Y ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Angiotensin (1 7); Angiotensin Converting Enzyme 2 (Ace2); Diabetes; Diabetic cardiomyopathy; Vascular complication

Indexed keywords

ANGIOTENSIN CONVERTING ENZYME 2; ANGIOTENSIN[1-7]; MESSENGER RNA; RAS PROTEIN;

CARDIOVASCULAR DISEASE; DIABETES MELLITUS; DISEASE COURSE; HEART DISEASE; INSULIN RESISTANCE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SYSTOLIC DYSFUNCTION; VASCULAR DISEASE;

EID: 84891420160     PISSN: 01435221     EISSN: None     Source Type: Journal    
DOI: 10.1042/CS20130344     Document Type: Review

References (116)

1. Roglic, G., Unwin, N., Bennett, P. H., Mathers, C., Tuomilehto, J., Nag, S., Connolly, V. and King, H. (2005) The burden of mortality attributable to diabetes: realistic estimates for the year 2000. Diabetes Care 28, 2130-2135
2. King, H., Aubert, R. E. and Herman, W. H. (1998) Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care 21, 1414-1431
3. Calcutt, N. A., Cooper, M. E., Kern, T. S. and Schmidt, A. M. (2009) Therapies for hyperglycaemia-induced diabetic complications: from animal models to clinical trials. Nat. Rev. Drug Discov. 8, 417-429
4. Botero, D. and Wolfsdorf, J. I. (2005) Diabetes mellitus in children and adolescents. Arch. Med. Res. 36, 281-290
5. Zimmet, P., Alberti, K. G. and Shaw, J. (2001) Global and societal implications of the diabetes epidemic. Nature 414, 782-787
6. Turner, R. C. and Holman, R. R. (1995) Lessons from UK prospective diabetes study. Diabetes Res. Clin. Pract. 28 (Suppl.), S151-S157
7. Giacco, F. and Brownlee, M. (2010) Oxidative stress and diabetic complications. Circ. Res. 107, 1058-1070
8. Jay, D., Hitomi, H. and Griendling, K. K. (2006) Oxidative stress and diabetic cardiovascular complications. Free Radic. Biol. Med. 40, 183-192
9. King, G. L. and Loeken, M. R. (2004) Hyperglycemia-induced oxidative stress in diabetic complications. Histochem. Cell Biol. 122, 333-338
10. Kuroki, T., Isshiki, K. and King, G. L. (2003) Oxidative stress: the lead or supporting actor in the pathogenesis of diabetic complications. J. Am. Soc. Nephrol. 14, S216-S220
11. Niedowicz, D. M. and Daleke, D. L. (2005) The role of oxidative stress in diabetic complications. Cell Biochem. Biophys. 43, 289-330
12. Sasaki, S. and Inoguchi, T. (2012) The role of oxidative stress in the pathogenesis of diabetic vascular complications. Diabetes Metab. J. 36, 255-261
13. Son, S. M., Whalin, M. K., Harrison, D. G., Taylor, W. R. and Griendling, K. K. (2004) Oxidative stress and diabetic vascular complications. Curr. Diabetes Rep. 4, 247-252
14. Wei, W., Liu, Q., Tan, Y., Liu, L., Li, X. and Cai, L. (2009) Oxidative stress, diabetes, and diabetic complications. Hemoglobin 33, 370-377
15. Yamagishi, S., Nakamura, K., Matsui, T., Ueda, S., Fukami, K. and Okuda, S. (2008) Agents that block advanced glycation end product (AGE)-RAGE (receptor for AGEs)-oxidative stress system: a novel therapeutic strategy for diabetic vascular complications. Expert Opin. Invest. Drugs 17, 983-996
16. Donoghue, M., Hsieh, F., Baronas, E., Godbout, K., Gosselin, M., Stagliano, N., Donovan, M., Woolf, B., Robison, K., Jeyaseelan, R. et al. (2000) A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ. Res. 87, E1-E9
17. Tipnis, S. R., Hooper, N. M., Hyde, R., Karran, E., Christie, G. and Turner, A. J. (2000) A human homolog of angiotensinconverting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase. J. Biol. Chem. 275, 33238-33243
18. Boudina, S. and Abel, E. D. (2007) Diabetic cardiomyopathy revisited. Circulation 115, 3213-3223
19. Poornima, I. G., Parikh, P. and Shannon, R. P. (2006) Diabetic cardiomyopathy: the search for a unifying hypothesis. Circ. Res. 98, 596-605
20. Kannel, W. B., Hjortland, M. and Castelli, W. P. (1974) Role of diabetes in congestive heart failure: the Framingham study. Am. J. Cardiol. 34, 29-34
21. Battiprolu, P. K., Gillette, T. G., Wang, Z. V., Lavandero, S. and Hill, J. A. (2010) Diabetic cardiomyopathy: mechanisms and therapeutic targets. Drug Discov. Today Dis. Mech. 7, e135-e143
22. Regan, T. J., Lyons, M. M., Ahmed, S. S., Levinson, G. E., Oldewurtel, H. A., Ahmad, M. R. and Haider, B. (1977) Evidence for cardiomyopathy in familial diabetes mellitus. J. Clin. Invest. 60, 884-899
23. Mizushige, K., Yao, L., Noma, T., Kiyomoto, H., Yu, Y., Hosomi, N., Ohmori, K. and Matsuo, H. (2000) Alteration in left ventricular diastolic filling and accumulation of myocardial collagen at insulin-resistant prediabetic stage of a type II diabetic rat model. Circulation 101, 899-907
24. Rubler, S., Dlugash, J., Yuceoglu, Y. Z., Kumral, T., Branwood, A. W. and Grishman, A. (1972) New type of cardiomyopathy associated with diabetic glomerulosclerosis. Am. J. Cardiol. 30, 595-602
25. Paul, M., Poyan Mehr, A. and Kreutz, R. (2006) Physiology of local renin-angiotensin systems. Physiol. Rev. 86, 747-803
26. Bader, M. (2013) ACE2, angiotensin-(1-7), and Mas: the other side of the coin. Pfl̈ugers Arch. 465, 79-85
27. Oudit, G. Y., Liu, G. C., Zhong, J., Basu, R., Chow, F. L., Zhou, J., Loibner, H., Janzek, E., Schuster, M., Penninger, J. M. et al. (2010) Human recombinant ACE2 reduces the progression of diabetic nephropathy. Diabetes 59, 529-538
28. Wang, W., Bodiga, S., Das, S. K., Lo, J., Patel, V. and Oudit, G. Y. (2012) Role of ACE2 in diastolic and systolic heart failure. Heart Fail. Rev. 17, 683-691
29. Ribeiro-Oliveira, Jr, A., Nogueira, A. I., Pereira, R. M., Boas, W. W., Dos Santos, R. A. and Simoes e Silva, A. C. (2008) The renin-angiotensin system and diabetes: an update. Vasc. Health Risk Manag. 4, 787-803
30. Bader, M. and Ganten, D. (2008) Update on tissue renin-angiotensin systems. J. Mol. Med. 86, 615-621
31. Mehta, P. K. and Griendling, K. K. (2007) Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system. Am. J. Physiol. Cell Physiol. 292, C82-C97
32. Li, W., Moore, M. J., Vasilieva, N., Sui, J., Wong, S. K., Berne, M. A., Somasundaran, M., Sullivan, J. L., Luzuriaga, K., Greenough, T. C. et al. (2003) Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature 426, 450-454
33. Crackower, M. A., Sarao, R., Oudit, G. Y., Yagil, C., Kozieradzki, I., Scanga, S. E., Oliveira-dos-Santos, A. J., da Costa, J., Zhang, L., Pei, Y. et al. (2002) Angiotensin-converting enzyme 2 is an essential regulator of heart function. Nature 417, 822-828
34. Oudit, G. Y., Kassiri, Z., Patel, M. P., Chappell, M., Butany, J., Backx, P. H., Tsushima, R. G., Scholey, J. W., Khokha, R. and Penninger, J. M. (2007) Angiotensin II-mediated oxidative stress and inflammation mediate the age-dependent cardiomyopathy in ACE2 null mice. Cardiovasc. Res. 75, 29-39
35. Kassiri, Z., Zhong, J., Guo, D., Basu, R., Wang, X., Liu, P. P., Scholey, J. W., Penninger, J. M. and Oudit, G. Y. (2009) Loss of angiotensin-converting enzyme 2 accelerates maladaptive left ventricular remodeling in response to myocardial infarction. Circ. Heart Fail. 2, 446-455
36. Patel, V. B., Bodiga, S., Fan, D., Das, S. K., Wang, Z., Wang, W., Basu, R., Zhong, J., Kassiri, Z. and Oudit, G. Y. (2012) Cardioprotective effects mediated by angiotensin II type 1 receptor blockade and enhancing angiotensin 1-7 in experimental heart failure in angiotensin-converting enzyme 2-null mice. Hypertension 59, 1195-1203
37. Bodiga, S., Zhong, J. C., Wang, W., Basu, R., Lo, J., Liu, G. C., Guo, D., Holland, S. M., Scholey, J. W., Penninger, J. M. et al. (2011) Enhanced susceptibility to biomechanical stress in ACE2 null mice is prevented by loss of the p47(phox) NADPH oxidase subunit. Cardiovasc. Res. 91, 151-161
38. Lo, J., Patel, V. B., Wang, Z., Levasseur, J., Kaufman, S., Penninger, J. M. and Oudit, G. Y. (2013) Angiotensin-converting enzyme 2 antagonizes angiotensin II-induced pressor response and NADPH oxidase activation in Wistar-Kyoto rats and spontaneously hypertensive rats. Exp. Physiol. 98, 109-122
39. Lovren, F., Pan, Y., Quan, A., Teoh, H., Wang, G., Shukla, P. C., Levitt, K. S., Oudit, G. Y., Al-Omran, M., Stewart, D. J. et al. (2008) Angiotensin converting enzyme-2 confers endothelial protection and attenuates atherosclerosis. Am. J. Physiol. Heart Circ. Physiol. 295, H1377-H1384
40. Thomas, M. C., Pickering, R. J., Tsorotes, D., Koitka, A., Sheehy, K., Bernardi, S., Toffoli, B., Nguyen-Huu, T. P., Head, G. A., Fu, Y. et al. (2010) Genetic Ace2 deficiency accentuates vascular inflammation and atherosclerosis in the ApoE knockout mouse. Circ. Res. 107, 888-897
41. Jin, H. Y., Song, B., Oudit, G. Y., Davidge, S. T., Yu, H. M., Jiang, Y. Y., Gao, P. J., Zhu, D. L., Ning, G., Kassiri, Z. et al. (2012) ACE2 deficiency enhances angiotensin II-mediated aortic profilin-1 expression, inflammation and peroxynitrite production. PLoS ONE 7, e38502
42. Santos, R. A., Simoes e Silva, A. C., Maric, C., Silva, D. M., Machado, R. P., de Buhr, I., Heringer-Walther, S., Pinheiro, S. V., Lopes, M. T., Bader, M. et al. (2003) Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc. Natl. Acad. Sci. U.S.A. 100, 8258-8263
43. Mercure, C., Yogi, A., Callera, G. E., Aranha, A. B., Bader, M., Ferreira, A. J., Santos, R. A., Walther, T., Touyz, R. M. and Reudelhuber, T. L. (2008) Angiotensin(1-7) blunts hypertensive cardiac remodeling by a direct effect on the heart. Circ. Res. 103, 1319-1326
44. Dzau, V. J. and Re, R. (1994) Tissue angiotensin system in cardiovascular medicine. A paradigm shift? Circulation 89, 493-498
45. Lavoie, J. L. and Sigmund, C. D. (2003) Minireview: overview of the renin-angiotensin system: an endocrine and paracrine system. Endocrinology 144, 2179-2183
46. Danser, A. H. and Schalekamp, M. A. (1996) Is there an internal cardiac renin-angiotensin system? Heart 76, 28-32
47. Paul, M., Wagner, J. and Dzau, V. J. (1993) Gene expression of the renin-angiotensin system in human tissues. Quantitative analysis by the polymerase chain reaction. J. Clin. Invest. 91, 2058-2064
48. Tahmasebi, M., Puddefoot, J. R., Inwang, E. R. and Vinson, G. P. (1999) The tissue renin-angiotensin system in human pancreas. J. Endocrinol. 161, 317-322
49. Wagner, J., Jan Danser, A. H., Derkx, F. H., de Jong, T. V., Paul, M., Mullins, J. J., Schalekamp, M. A. and Ganten, D. (1996) Demonstration of renin mRNA, angiotensinogen mRNA, and angiotensin converting enzyme mRNA expression in the human eye: evidence for an intraocular renin-angiotensin system. Br. J. Ophthalmol. 80, 159-163
50. Tikellis, C., Johnston, C. I., Forbes, J. M., Burns, W. C., Thomas, M. C., Lew, R. A., Yarski, M., Smith, A. I. and Cooper, M. E. (2004) Identification of angiotensin converting enzyme in the rodent retina. Curr. Eye Res. 29, 419-427
51. Baltatu, O., Silva, Jr, J. A., Ganten, D. and Bader, M. (2000) The brain renin-angiotensin system modulates angiotensin II-induced hypertension and cardiac hypertrophy. Hypertension 35, 409-412
52. Abuissa, H., Jones, P. G., Marso, S. P. and O'Keefe, Jr, J. H. (2005) Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prevention of Type 2 diabetes: a meta-analysis of randomized clinical trials. J. Am. Coll. Cardiol. 46, 821-826
53. Yusuf, S., Gerstein, H., Hoogwerf, B., Pogue, J., Bosch, J., Wolffenbuttel, B. H., Zinman, B. and HOPE Study Investigators (2001) Ramipril and the development of diabetes. JAMA 286, 1882-1885
54. Heart Outcomes Prevention Evaluation Study Investigators (2000) Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 355, 253-259
55. Gress, T. W., Nieto, F. J., Shahar, E., Wofford, M. R. and Brancati, F. L. (2000) Hypertension and antihypertensive therapy as risk factors for Type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study. N. Engl. J. Med. 342, 905-912
56. Vermes, E., Ducharme, A., Bourassa, M. G., Lessard, M., White, M., Tardif, J. C. and Studies Of Left Ventricular Dysfunction (2003) Enalapril reduces the incidence of diabetes in patients with chronic heart failure: insight from the Studies Of Left Ventricular Dysfunction (SOLVD). Circulation 107, 1291-1296
57. Niklason, A., Hedner, T., Niskanen, L., Lanke, J. and Captopril Prevention Project Study Group (2004) Development of diabetes is retarded by ACE inhibition in hypertensive patients: a subanalysis of the Captopril Prevention Project (CAPPP). J. Hypertens. 22, 645-652
58. Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H. H., Remuzzi, G., Snapinn, S. M., Zhang, Z., Shahinfar, S. et al. (2001) Effects of losartan on renal and cardiovascular outcomes in patients with Type 2 diabetes and nephropathy. N. Engl. J. Med. 345, 861-869
59. Bindom, S. M. and Lazartigues, E. (2009) The sweeter side of ACE2: physiological evidence for a role in diabetes. Mol. Cell. Endocrinol. 302, 193-202
60. Bedard, K. and Krause, K. H. (2007) The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. Physiol. Rev. 87, 245-313
61. Maechler, P., Jornot, L. and Wollheim, C. B. (1999) Hydrogen peroxide alters mitochondrial activation and insulin secretion in pancreatic β cells. J. Biol. Chem. 274, 27905-27913
62. Kaneto, H., Xu, G., Song, K. H., Suzuma, K., Bonner-Weir, S., Sharma, A. and Weir, G. C. (2001) Activation of the hexosamine pathway leads to deterioration of pancreatic β-cell function through the induction of oxidative stress. J. Biol. Chem. 276, 31099-31104
63. Chu, K. Y., Lau, T., Carlsson, P. O. and Leung, P. S. (2006) Angiotensin II type 1 receptor blockade improves β-cell function and glucose tolerance in a mouse model of Type 2 diabetes. Diabetes 55, 367-374
64. Matsuoka, T., Kajimoto, Y., Watada, H., Kaneto, H., Kishimoto, M., Umayahara, Y., Fujitani, Y., Kamada, T., Kawamori, R. and Yamasaki, Y. (1997) Glycation-dependent, reactive oxygen species-mediated suppression of the insulin gene promoter activity in HIT cells. J. Clin. Invest. 99, 144-150
65. Carlsson, P. O., Berne, C. and Jansson, L. (1998) Angiotensin II and the endocrine pancreas: effects on islet blood flow and insulin secretion in rats. Diabetologia 41, 127-133
66. Torlone, E., Rambotti, A. M., Perriello, G., Botta, G., Santeusanio, F., Brunetti, P. and Bolli, G. B. (1991) ACE-inhibition increases hepatic and extrahepatic sensitivity to insulin in patients with Type 2 (non-insulin-dependent) diabetes mellitus and arterial hypertension. Diabetologia 34, 119-125
67. Seikaly, M. G., Arant, Jr, B. S. and Seney, Jr, F. D. (1990) Endogenous angiotensin concentrations in specific intrarenal fluid compartments of the rat. J. Clin. Invest. 86, 1352-1357
68. Tojo, A., Asaba, K. and Onozato, M. L. (2007) Suppressing renal NADPH oxidase to treat diabetic nephropathy. Expert Opin. Ther. Targets 11, 1011-1018
69. Leehey, D. J., Singh, A. K., Alavi, N. and Singh, R. (2000) Role of angiotensin II in diabetic nephropathy. Kidney Int. Suppl. 77, S93-S98
70. Ling, H., Vamvakas, S., Schaefer, L., Schnittler, H. J., Schaefer, R. M. and Heidland, A. (1995) Angiotensin-II-induced cell hypertrophy: potential role of impaired proteolytic activity in cultured LLC-PK1 cells. Nephrol. Dial. Transplant. 10, 1305-1312
71. Mori, J., Basu, R., McLean, B. A., Das, S. K., Zhang, L., Patel, V. B., Wagg, C. S., Kassiri, Z., Lopaschuk, G. D. and Oudit, G. Y. (2012) Agonist-induced hypertrophy and diastolic dysfunction are associated with selective reduction in glucose oxidation: a metabolic contribution to heart failure with normal ejection fraction. Circ. Heart Fail. 5, 493-503
72. Bendall, J. K., Cave, A. C., Heymes, C., Gall, N. and Shah, A. M. (2002) Pivotal role of a gp91(phox)-containing NADPH oxidase in angiotensin II-induced cardiac hypertrophy in mice. Circulation 105, 293-296
73. de Cavanagh, E. M., Ferder, M., Inserra, F. and Ferder, L. (2009) Angiotensin II, mitochondria, cytoskeletal, and extracellular matrix connections: an integrating viewpoint. Am. J. Physiol. Heart Circ. Physiol. 296, H550-H558
74. Patel, V. B., Bodiga, S., Basu, R., Das, S. K., Wang, W., Wang, Z., Lo, J., Grant, M. B., Zhong, J., Kassiri, Z. et al. (2012) Loss of angiotensin-converting enzyme-2 exacerbates diabetic cardiovascular complications and leads to systolic and vascular dysfunction: a critical role of the angiotensin II/AT1 receptor axis. Circ. Res. 110, 1322-1335
75. Wong, W. T., Tian, X. Y., Xu, A., Ng, C. F., Lee, H. K., Chen, Z. Y., Au, C. L., Yao, X. and Huang, Y. (2010) Angiotensin II type 1 receptor-dependent oxidative stress mediates endothelial dysfunction in Type 2 diabetic mice. Antioxid. Redox Signal. 13, 757-768
76. Taguchi, K., Kobayashi, T., Takenouchi, Y., Matsumoto, T. and Kamata, K. (2011) Angiotensin II causes endothelial dysfunction via the GRK2/Akt/eNOS pathway in aortas from a murine Type 2 diabetic model. Pharmacol. Res. 64, 535-546
77. Shatanawi, A., Romero, M. J., Iddings, J. A., Chandra, S., Umapathy, N. S., Verin, A. D., Caldwell, R. B. and Caldwell, R. W. (2011) Angiotensin II-induced vascular endothelial dysfunction through RhoA/Rho kinase/p38 mitogen-activated protein kinase/arginase pathway. Am. J. Physiol. Cell Physiol. 300, C1181-C1192
78. Yaghini, F. A., Song, C. Y., Lavrentyev, E. N., Ghafoor, H. U., Fang, X. R., Estes, A. M., Campbell, W. B. and Malik, K. U. (2010) Angiotensin II-induced vascular smooth muscle cell migration and growth are mediated by cytochrome P450 1B1-dependent superoxide generation. Hypertension 55, 1461-1467
79. Griendling, K. K., Minieri, C. A., Ollerenshaw, J. D. and Alexander, R. W. (1994) Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ. Res. 74, 1141-1148
80. Touyz, R. M., Yao, G. and Schiffrin, E. L. (2005) Role of the actin cytoskeleton in angiotensin II signaling in human vascular smooth muscle cells. Can. J. Physiol. Pharmacol. 83, 91-97
81. Bascands, J. L., Girolami, J. P., Troly, M., Escargueil-Blanc, I., Nazzal, D., Salvayre, R. and Blaes, N. (2001) Angiotensin II induces phenotype-dependent apoptosis in vascular smooth muscle cells. Hypertension 38, 1294-1299
82. Epelman, S., Tang, W. H., Chen, S. Y., Van Lente, F., Francis, G. S. and Sen, S. (2008) Detection of soluble angiotensinconverting enzyme 2 in heart failure: insights into the endogenous counter-regulatory pathway of the reninangiotensin-aldosterone system. J. Am. Coll. Cardiol. 52, 750-754
83. Epelman, S., Shrestha, K., Troughton, R. W., Francis, G. S., Sen, S., Klein, A. L. and Tang, W. H. (2009) Soluble angiotensin-converting enzyme 2 in human heart failure: relation with myocardial function and clinical outcomes. J. Card. Fail. 15, 565-571
84. Soro-Paavonen, A., Gordin, D., Forsblom, C., Rosengard-Barlund, M., Waden, J., Thorn, L., Sandholm, N., Thomas, M. C. and Groop, P. H. (2012) Circulating ACE2 activity is increased in patients with Type 1 diabetes and vascular complications. J. Hypertens. 30, 375-383
85. Dong, B., Yu, Q. T., Dai, H. Y., Gao, Y. Y., Zhou, Z. L., Zhang, L., Jiang, H., Gao, F., Li, S. Y., Zhang, Y. H. et al. (2012) Angiotensin-converting enzyme-2 overexpression improves left ventricular remodeling and function in a rat model of diabetic cardiomyopathy. J. Am. Coll. Cardiol. 59, 739-747
86. Murca, T. M., Moraes, P. L., Capuruco, C. A., Santos, S. H., Melo, M. B., Santos, R. A., Shenoy, V., Katovich, M. J., Raizada, M. K. and Ferreira, A. J. (2012) Oral administration of an angiotensin-converting enzyme 2 activator ameliorates diabetes-induced cardiac dysfunction. Regul. Pept. 177, 107-115
87. Murca, T. M., Almeida, T. C., Raizada, M. K. and Ferreira, A. J. (2012) Chronic activation of endogenous angiotensin-converting enzyme 2 protects diabetic rats from cardiovascular autonomic dysfunction. Exp. Physiol. 97, 699-709
88. Yousif, M. H., Dhaunsi, G. S., Makki, B. M., Qabazard, B. A., Akhtar, S. and Benter, I. F. (2012) Characterization of angiotensin-(1-7) effects on the cardiovascular system in an experimental model of type-1 diabetes. Pharmacol. Res. 66, 269-275
89. Al-Maghrebi, M., Benter, I. F. and Diz, D. I. (2009) Endogenous angiotensin-(1-7) reduces cardiac ischemia-induced dysfunction in diabetic hypertensive rats. Pharmacol. Res. 59, 263-268
90. Basu, R., Oudit, G. Y., Wang, X., Zhang, L., Ussher, J. R., Lopaschuk, G. D. and Kassiri, Z. (2009) Type 1 diabetic cardiomyopathy in the Akita (Ins2WT/C96Y) mouse model is characterized by lipotoxicity and diastolic dysfunction with preserved systolic function. Am. J. Physiol. Heart Circ. Physiol. 297, H2096-H2108
91. Tikellis, C., Pickering, R., Tsorotes, D., Du, X. J., Kiriazis, H., Nguyen-Huu, T. P., Head, G. A., Cooper, M. E. and Thomas, M. C. (2012) Interaction of diabetes and ACE2 in the pathogenesis of cardiovascular disease in experimental diabetes. Clin. Sci. 123, 519-529
92. Benter, I. F., Yousif, M. H., Cojocel, C., Al-Maghrebi, M. and Diz, D. I. (2007) Angiotensin-(1-7) prevents diabetes-induced cardiovascular dysfunction. Am. J. Physiol. Heart Circ. Physiol. 292, H666-H672
93. Ebermann, L., Spillmann, F., Sidiropoulos, M., Escher, F., Heringer-Walther, S., Schultheiss, H. P., Tschope, C. and Walther, T. (2008) The angiotensin-(1-7) receptor agonist AVE0991 is cardioprotective in diabetic rats. Eur. J. Pharmacol. 590, 276-280
94. Singh, K., Singh, T. and Sharma, P. L. (2011) Beneficial effects of angiotensin (1-7) in diabetic rats with cardiomyopathy. Ther. Adv. Cardiovasc. Dis. 5, 159-167
95. Fraga-Silva, R. A., Costa-Fraga, F. P., Murca, T. M., Moraes, P. L., Martins Lima, A., Lautner, R. Q., Castro, C. H., Soares, C. M., Borges, C. L., Nadu, A. P. et al. (2013) Angiotensin-converting enzyme 2 activation improves endothelial function. Hypertension 61, 1233-1238
96. Dharmani, M., Mustafa, M. R., Achike, F. I. and Sim, M. K. (2007) Effects of angiotensin 1-7 on the actions of angiotensin II in the renal and mesenteric vasculature of hypertensive and streptozotocin-induced diabetic rats. Eur. J. Pharmacol. 561, 144-150
97. Oliveira, M. A., Carvalho, M. H., Nigro, D., Passaglia Rde, C. and Fortes, Z. B. (2002) Angiotensin-(1-7) and bradykinin interaction in diabetes mellitus: in vivo study. Peptides 23, 1449-1455
98. Rastelli, V. M., Oliveira, M. A., dos Santos, R., de Cassia Tostes Passaglia, R., Nigro, D., de Carvalho, M. H. and Fortes, Z. B. (2007) Lack of potentiation of bradykinin by angiotensin-(1-7) in a Type 2 diabetes model: role of insulin. Peptides 28, 1040-1049
99. Tassone, E. J., Sciacqua, A., Andreozzi, F., Presta, I., Perticone, M., Carnevale, D., Casaburo, M., Hribal, M. L., Sesti, G. and Perticone, F. (2013) Angiotensin (1-7) counteracts the negative effect of angiotensin II on insulin signalling in HUVECs. Cardiovasc. Res. 99, 129-136
100. Akhtar, S., Yousif, M. H., Dhaunsi, G. S., Chandrasekhar, B., Al-Farsi, O. and Benter, I. F. (2012) Angiotensin-(1-7) inhibits epidermal growth factor receptor transactivation via a Mas receptor-dependent pathway. Br. J. Pharmacol. 165, 1390-1400
101. Jarajapu, Y. P., Bhatwadekar, A. D., Caballero, S., Hazra, S., Shenoy, V., Medina, R., Kent, D., Stitt, A. W., Thut, C., Finney, E. M. et al. (2013) Activation of the ACE2/angiotensin-(1-7)/Mas receptor axis enhances the reparative function of dysfunctional diabetic endothelial progenitors. Diabetes 62, 1258-1269
102. Beckman, J. A., Creager, M. A. and Libby, P. (2002) Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA 287, 2570-2581
103. Sluimer, J. C., Gasc, J. M., Hamming, I., van Goor, H., Michaud, A., van den Akker, L. H., Jutten, B., Cleutjens, J., Bijnens, A. P., Corvol, P. et al. (2008) Angiotensin-converting enzyme 2 (ACE2) expression and activity in human carotid atherosclerotic lesions. J. Pathol. 215, 273-279
104. Purushothaman, K. R., Krishnan, P., Purushothaman, M., Wiley, J., Alviar, C. L., Ruiz, F. J., Zubatov, Y., Kini, A. S., Sharma, S. K., Fuster, V. et al. (2013) Expression of angiotensin-converting enzyme 2 and its end product angiotensin 1-7 is increased in diabetic atheroma: implications for inflammation and neovascularization. Cardiovasc. Pathol. 22, 42-48
105. Dong, B., Zhang, C., Feng, J. B., Zhao, Y. X., Li, S. Y., Yang, Y. P., Dong, Q. L., Deng, B. P., Zhu, L., Yu, Q. T. et al. (2008) Overexpression of ACE2 enhances plaque stability in a rabbit model of atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 28, 1270-1276
106. Urata, H., Healy, B., Stewart, R. W., Bumpus, F. M. and Husain, A. (1990) Angiotensin II-forming pathways in normal and failing human hearts. Circ. Res. 66, 883-890
107. Urata, H., Kinoshita, A., Misono, K. S., Bumpus, F. M. and Husain, A. (1990) Identification of a highly specific chymase as the major angiotensin II-forming enzyme in the human heart. J. Biol. Chem. 265, 22348-22357
108. Jenne, D. E. and Tschopp, J. (1991) Angiotensin II-forming heart chymase is a mast-cell-specific enzyme. Biochem. J. 276, 567-568
109. Wei, C. C., Hase, N., Inoue, Y., Bradley, E. W., Yahiro, E., Li, M., Naqvi, N., Powell, P. C., Shi, K., Takahashi, Y. et al. (2010) Mast cell chymase limits the cardiac efficacy of Ang I-converting enzyme inhibitor therapy in rodents. J. Clin. Invest. 120, 1229-1239
110. Mackins, C. J., Kano, S., Seyedi, N., Schafer, U., Reid, A. C., Machida, T., Silver, R. B. and Levi, R. (2006) Cardiac mast cell-derived renin promotes local angiotensin formation, norepinephrine release, and arrhythmias in ischemia/reperfusion. J. Clin. Invest. 116, 1063-1070
111. Hara, M., Ono, K., Hwang, M. W., Iwasaki, A., Okada, M., Nakatani, K., Sasayama, S. and Matsumori, A. (2002) Evidence for a role of mast cells in the evolution to congestive heart failure. J. Exp. Med. 195, 375-381
112. Juillerat, L., Nussberger, J., Menard, J., Mooser, V., Christen, Y., Waeber, B., Graf, P. and Brunner, H. R. (1990) Determinants of angiotensin II generation during converting enzyme inhibition. Hypertension 16, 564-572
113. van de Wal, R. M., Plokker, H. W., Lok, D. J., Boomsma, F., van der Horst, F. A., van Veldhuisen, D. J., van Gilst, W. H. and Voors, A. A. (2006) Determinants of increased angiotensin II levels in severe chronic heart failure patients despite ACE inhibition. Int. J. Cardiol. 106, 367-372
114. Roig, E., Perez-Villa, F., Morales, M., Jimenez, W., Orus, J., Heras, M. and Sanz, G. (2000) Clinical implications of increased plasma angiotensin II despite ACE inhibitor therapy in patients with congestive heart failure. Eur. Heart J. 21, 53-57
115. Zhong, J. C., Basu, R., Guo, D., Chow, F. L., Byrns, S., Shuster, M., Loibner, H., Wang, X., Penninger, J. M., Kassiri, Z. et al. (2010) Angiotensin converting enzyme 2 suppresses pathological hypertrophy, myocardial fibrosis and cardiac dysfunction. Circulation 122, 717-728
116. Oudit, G. Y. and Penninger, J. M. (2011) Recombinant human angiotensin-converting enzyme 2 as a new renin-angiotensin system peptidase for heart failure therapy. Curr. Heart Fail. Rep. 8, 176-183